FHLKX
Price
$10.31
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
OCGCX
Price
$12.71
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
Ad is loading...

FHLKX vs OCGCX

Header iconFHLKX vs OCGCX Comparison
Open Charts FHLKX vs OCGCXBanner chart's image
Fidelity Health Savings K
Price$10.31
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
JPMorgan Investor Conservative Growth C
Price$12.71
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
FHLKX vs OCGCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FHLKX vs. OCGCX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FHLKX is a StrongBuy and OCGCX is a Hold.

FUNDAMENTALS
Fundamentals
OCGCX has more cash in the bank: 3.97B vs. FHLKX (59.8M). FHLKX pays higher dividends than OCGCX: FHLKX (2.95) vs OCGCX (2.30). FHLKX was incepted earlier than OCGCX: FHLKX (5 years) vs OCGCX (27 years). FHLKX is a more actively managed with annual turnover of: 46.00 vs. OCGCX (5.00). FHLKX has a lower initial minimum investment than OCGCX: FHLKX (0) vs OCGCX (500). FHLKX (13.22) and OCGCX (12.64) have marching annual gain over last year.
FHLKXOCGCXFHLKX / OCGCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years27 years-
Gain YTD7.2287.39498%
Front LoadN/AN/A-
Min. Initial Investment0500-
Min. Initial Investment IRAN/AN/A-
Net Assets59.8M3.97B2%
Annual Yield % from dividends2.952.30128%
Returns for 1 year13.2212.64105%
Returns for 3 years-1.04-3.3032%
Returns for 5 yearsN/A9.29-
Returns for 10 yearsN/A14.79-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ETADX20.090.03
+0.15%
Eventide Dividend Growth A
ABMIX25.58-0.02
-0.08%
AMG River Road Mid Cap Value I
VBIAX50.67-0.04
-0.08%
Vanguard Balanced Index Adm
FGRTX26.39-0.07
-0.26%
Fidelity Mega Cap Stock
BRKRX13.95-0.10
-0.71%
MFS Blended Research Em Mkts Eq R1